Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

enasidenib

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020

- PMLiVE

Celgene boosts IO presence with Immatics deal

Immatics technology promises to go beyond CAR-T capabilities

- PMLiVE

Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

Celgene building

Triplet approvals for myeloma boost Celgene in Q2

Surge in approvals and pipeline as merger nears

- PMLiVE

Celgene cuts back Jounce alliance ahead of BMS merger

Next-gen immuno-oncology alliance lives on

- PMLiVE

Otezla scores new indication as speculation over potential buyers grows

Who will buy blockbuster psoriasis drug?

Bristol Myers Squibb logo

Faced with regulator’s merger concerns, BMS want to offload Otezla

Sell-off will mean merger delay

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links